Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: Data from the SARA study

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 3, 2009, Pages 168-173

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Calderón, Alberto ^c   Echarri, Rocio ^b   Barrios, Sara ^a   Navarro Cid, Josefa ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c Primary Care Center Rosa de Luxemburgo   (Spain)

Author keywords

Candesartan; Diabetes; Electrocardiogram; Left ventricular hypertrophy; Regression

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIHYDROPYRIDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ADULT; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CRITERION VARIABLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DIABETES COMPLICATIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREVALENCE; SPAIN; TETRAZOLES;

EID: 69849088101     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309343596     Document Type: Article

References (29)

1. Bell DS Hypertension and diabetes: A toxic combination. Endocr Pract 2008;14:1031-9.
2. Umpierrez GE, Smiley D., Robalino G. et al. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2009;94:609-14.
3. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-9.
4. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
5. Barrios V., Escobar C., Calderon A., Ribas L., Marti D., Asin E. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press 2008;17:110-15.
6. Palmieri V., Bella JN, Arnett DK et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001;103:102-07.
7. Dawson A., Morris AD, Struthers AD The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005;48:1971-9.
8. Struthers AD, Morris AD Screening for and treating left-ventricular abnormalities in diabetes mellitus: A new way of reducing cardiac deaths. Lancet 2002;359:1430-2.
9. Lindholm LH, Ibsen H., Dahlöf B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004-10.
10. Levy D., Salomon M., D'Agostino RB, Belanger AJ, Kannel WB Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.
11. Bella JN, Devereux RB Is echocardiography essential in the management of newly diagnosed hypertension? Am J Hypertens 2006;19:1156-7.
12. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-72.
13. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
14. Okin PM, Devereux RB, Jern SS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.
15. Isobe N., Taniguchi K., Oshima S. et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002;66:993-9.
16. Barrios V., Calderon A., Escobar C. et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice. The SARA study. J Hypertens 2007;25:1967-73.
17. Escobar C., Barrios V., Calderón A. et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: Data from the SARA study. J Clin Hypertens 2008;10:208-14.
18. Casale PN, Devereux RB, Kligfield P. et al. Electrocardiographic detection of left ventricular hypertrophy: Development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572-80.
19. Okin PM, Roman MJ, Devereux RB, Pickering TG, Borer JS, Kligfield P. Time-voltage area of the 12-lead electrocardiogram. Detection of left ventricular hypertrophy. Hypertension 1998;31:937-42.
20. Okin PM, Roman MJ, Devereaux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-23.
21. Alfakih K., Walters K., Jones T., Ridgway J., Hall AS, Sivananthan M. New gender-specific partition values for ECG criteria of left ventricular hypertrophy. Recalibration against cardiac MRI. Hypertension 2004;44:175-9.
22. Barrios V., Escobar C., Calderón A. et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006;7:236-42.
23. Okin PM, Devereux RB, Harris KE et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007;50:984-90.
24. Verdecchia P., Reboldi G., Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
25. Galderisi M., Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85-9.
26. Barrios V., Escobar C., Calderon A. et al. Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels 2009; (In press).
27. Okin PM, Devereux RB, Gerdts E. et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006;113:1588-96.
28. Barrios V., Escobar C., Calderón A., Vegazo O., Fernandez R., Asín E. Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. Diabetes Res Clin Pract 2007;77:492-3.
29. Okin PM, Devereux RB, Jern S., Kjeldsen SE, Julius S., Dählof B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: The losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000;36:766-73.